Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis
Open Access
- 19 November 2019
- journal article
- review article
- Published by Wiley in Journal of Diabetes Research
- Vol. 2019, 1-8
Abstract
Background. Accumulating evidence suggests that patients with type 2 diabetes mellitus and hyperinsulinemia are at an increased risk of developing malignancies. It remains to be fully elucidated whether the use of metformin, an insulin sensitizer, and/or sulfonylureas, insulin secretagogues, affects cancer incidence in subjects with type 2 diabetes mellitus. Objective. A systematic review and meta-analysis was performed to compare the risk of cancer incidence associated with monotherapy with metformin compared with monotherapy with sulfonylureas in type 2 diabetes mellitus patients. Methods. Search was performed throughout MEDLINE/PubMed, EMBASE, Google Scholar, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov up until December 2018. In this meta-analysis, each raw data (unadjusted) and study-specific (adjusted) relative risks (RRs) was combined and the pooled unadjusted and adjusted RRs with the 95% CI were calculated using the random-effects model with inverse-variance weighting. Heterogeneity among the studies was evaluated using statistics. Publication bias was evaluated using the funnel plot asymmetry test. The Newcastle-Ottawa scale (NOS) was used to assess the study quality. Results. A total of 8 cohort studies were included in the meta-analysis. Obvious heterogeneity was noted, and monotherapy with metformin was associated with a lower risk of cancer incidence (unadjusted , 95% CI: 0.55-0.99, , ; adjusted , 95% CI: 0.54–1.07, , ) compared with monotherapy with sulfonylurea, using the random-effects model with inverse-variance weighting. Conclusions. According to this review, the monotherapy with metformin appears to be associated with a lower risk of cancer incidence than monotherapy with sulfonylurea in patients with type 2 diabetes. This analysis is mainly based on cohort studies, and our findings underscore the need for large-scale randomized controlled trials to establish the effect of metformin monotherapy, relative to sulfonylureas monotherapy on cancer.
Keywords
This publication has 27 references indexed in Scilit:
- Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2013
- Metformin and the Risk of CancerDiabetes Care, 2012
- The Influence of Type 2 Diabetes and Glucose-Lowering Therapies on Cancer Risk in the TaiwaneseExperimental Diabetes Research, 2012
- Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea DerivativesDiabetes Care, 2011
- Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetesMetabolism, 2011
- Use of sulphonylurea and cancer in type 2 diabetes—The Hong Kong Diabetes RegistryDiabetes Research and Clinical Practice, 2010
- Diabetes and cancerEndocrine-Related Cancer, 2009
- Mitigating micro- and macro-vascular complications of diabetes beginning in adolescenceVascular Health and Risk Management, 2009
- Insulin and insulin-like growth factor signalling in neoplasiaNature Reviews Cancer, 2008
- Mechanisms of Disease: pathway-selective insulin resistance and microvascular complications of diabetesNature Clinical Practice Endocrinology & Metabolism, 2005